Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Sep;7(5):1130-1136.
doi: 10.1016/j.euf.2020.09.017. Epub 2020 Oct 6.

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

Christian Daniel Fankhauser  1 , Ben Tran  2 , Manuel Pedregal  3 , José Manuel Ruiz-Morales  4 , Egon Gonzalez-Billalabeitia  5 , Anna Patrikidou  6 , Eitan Amir  7 , Christoph Seidel  8 , Carsten Bokemeyer  8 , Thomas Hermanns  1 , Alexey Rumyantsev  9 , Alexey Tryakin  9 , Margarida Brito  10 , Aude Fléchon  11 , Edmon M Kwan  2 , Tina Cheng  4 , Daniel Castellano  12 , Xavier Garcia Del Muro  13 , Anis A Hamid  14 , Margaret Ottaviano  15 , Giovanella Palmieri  15 , Robert Kitson  6 , Alison Reid  6 , Daniel Y C Heng  4 , Philippe L Bedard  7 , Christopher J Sweeney  3 , Jean M Connors  16
Affiliations
Free article

A Risk-benefit Analysis of Prophylactic Anticoagulation for Patients with Metastatic Germ Cell Tumours Undergoing First-line Chemotherapy

Christian Daniel Fankhauser et al. Eur Urol Focus. 2021 Sep.
Free article

Abstract

Background: It remains unclear which patients with metastatic germ cell tumours (mGCTs) need prophylactic anticoagulation to prevent venous thromboembolic events (VTEs).

Objective: To assess the risk and onset of VTEs stratified by risk factors.

Design, setting, and participants: This multi-institutional retrospective dataset included mGCT patients treated with first-line platinum-based chemotherapy.

Intervention: Patients with prophylactic anticoagulation were excluded.

Outcome measurements and statistical analysis: A regression analysis was performed to select risk factors for VTEs. The simulated number needed to treat (NNT) and the number needed to harm (NNH) with prophylactic anticoagulation were calculated based on the cumulative incidences retrieved from this study and hazard rates of recently published trials describing the efficacy of prophylactic anticoagulation to prevent VTEs and the risk of bleeding events.

Results and limitations: From 1120 patients, 121 (11%) had a VTE, which occurred prior to chemotherapy in 49 (4%) and on or after chemotherapy in 72 (6%). Six patients (<1%) had a bleeding event without anticoagulation. After backward regression, the one risk factor for a VTE during or after chemotherapy was the use of a venous access device. The simulated cumulative VTE incidence from prophylactic anticoagulation for patients on or after chemotherapy would translate into an NNT of 45 (95% confidence interval [CI] 36-56) and an NNH of 186 (95% CI 87-506). Limitations are mainly related to the retrospective nature of the study.

Conclusions: The mGCTs associated VTEs are most common before and during, but not after, chemotherapy. Avoiding venous access device and/or prophylactic anticoagulation with an acceptable risk-benefit profile may decrease VTE occurring on chemotherapy.

Patient summary: We found that venous thromboembolic events (VTEs) occur rarely after chemotherapy. Based on experience of prophylactic anticoagulation in other cancers, we conclude that the risk of VTE in men undergoing chemotherapy for metastatic germ cell tumours can be decreased by thromboprophylaxis with a reasonable risk-benefit profile and by avoidance of venous access devices.

Keywords: Deep vein thrombosis; Germ cell tumour; Pulmonary embolism; Testicular cancer; Venous access device; Venous thromboembolism.

PubMed Disclaimer

MeSH terms